Xeris Biopharma (NASDAQ:XERS) Stock: Insider Beth Hecht Sells 16,666 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total value of $156,827.06. Following the transaction, the insider directly owned 1,111,130 shares in the company, valued at approximately $10,455,733.30. This represents a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Tuesday, September 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.49, for a total value of $141,494.34.
• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.01, for a total transaction of $133,494.66.

Xeris Biopharma Trading Down 1.8%

XERS stock traded down $0.17 during mid-day trading on Friday, reaching $9.08. 1,375,716 shares of the stock traded hands, compared to its average volume of 1,988,684. Xeris Biopharma Holdings, Inc. has a one year low of $5.25 and a one year high of $11.33. The stock has a market capitalization of $1.66 billion, a PE ratio of -82.55 and a beta of 0.53. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. The business has a 50-day moving average price of $8.45 and a two-hundred day moving average price of $7.29.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The firm had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Equities research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on XERS. Barclays boosted their price objective on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Leerink Partners boosted their target price on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $12.80.

Institutional Trading of Xeris Biopharma

Large investors have recently modified their holdings of the company. Allworth Financial LP purchased a new position in Xeris Biopharma during the 2nd quarter worth $34,000. KBC Group NV purchased a new stake in shares of Xeris Biopharma in the 1st quarter worth $27,000. State of Wyoming bought a new position in shares of Xeris Biopharma during the 2nd quarter worth $52,000. Integrated Wealth Concepts LLC bought a new position in shares of Xeris Biopharma during the 2nd quarter worth $74,000. Finally, Kingsview Wealth Management LLC purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at $78,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.